Get the Stockscreener App
3.28
6.02%
-0.21
Aclaris Therapeutics Inc stock is traded at $3.28, with a volume of 2.46M.
It is down -6.02% in the last 24 hours and down -38.35% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
See More
Previous Close:
$3.49
Open:
$3.51
24h Volume:
2.46M
Relative Volume:
0.51
Market Cap:
$482.81M
Revenue:
$8.37M
Net Income/Loss:
$-69.66M
P/E Ratio:
-5.853
EPS:
-0.5604
Net Cash Flow:
$-51.45M
1W Performance:
-14.36%
1M Performance:
-38.35%
6M Performance:
-17.59%
1Y Performance:
+60.00%
1-Day Range:
$3.245
$3.53
1-Week Range:
$3.245
$3.835
52-Week Range:
$1.88
$6.5999
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.28 | 482.81M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-26 | Initiated | Canaccord Genuity | Buy |
| May-05-26 | Initiated | Guggenheim | Buy |
| Apr-16-26 | Initiated | Oppenheimer | Outperform |
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics, Inc. (ACRS) options chain - Yahoo Finance UK
MCPMF Stock Price and Chart — OTC:MCPMF - TradingView
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity - Investing.com
Aclaris Therapeutics, Inc. (8AT.F) stock price, news, quote and history - Yahoo Finance UK
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Eastern Progress
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Eastern Progress
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating - Investing.com
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com South Africa
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com Nigeria
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts - Investing.com
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts - Investing.com India
Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts By Investing.com - Investing.com UK
Aclaris CEO to Detail Drug Pipeline at Cantor Conference - MyChesCo
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Investing News Network
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com South Africa
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com Australia
Canaccord initiates Aclaris stock with buy rating on pipeline potential By Investing.com - Investing.com Canada
Canaccord initiates Aclaris stock with buy rating on pipeline potential - Investing.com India
CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target - Yahoo Finance
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com India
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com Canada
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Aclaris stock rating on asthma data By Investing.com - Investing.com UK
ETFs Investing in Aclaris Therapeutics, Inc. Stocks - TradingView
Aclaris Therapeutics (NASDAQ:ACRS) Stock: What Comes Next? - Kalkine Media
Aclaris Therapeutics (NASDAQ:ACRS) Trading 4.7% HigherWhat's Next? - MarketBeat
Aclaris Therapeutics (ACRS) Edges Lower by 1.37% as Shares Test Key Technical FloorRevenue Growth Stocks - vinanet.vn
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - MyChesCo
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - MarketBeat
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Zacks Investment Research
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Yahoo Finance
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - The Globe and Mail
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - MarketBeat
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):